We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




DNA Hypomethylation Predisposes to Type II Diabetes

By LabMedica International staff writers
Posted on 12 Jan 2012
A novel genomic screening technique that was used to compare DNA methylation variations between a group of individuals with type II diabetes and a group of normal individuals detected specific regions of hypomethylation in the DNA of the diabetes group.

Investigators at the Hebrew University of Jerusalem (Israel) designed a stepwise study to search for disease-contributing DNA methylation variations. More...
First, a pool based, genome-scale screen was carried out among 1169 type II diabetes cases and control individuals. Next, in-depth analyses were performed at selected top-ranking regions.

Results published in the January 15, 2012, online edition of the journal Human Molecular Genetics revealed an excess of differentially methylated sites in genomic regions that were previously associated with type II diabetes through genetic studies. A clear-cut region of hypomethylation was identified in the DNA of the type II diabetes cases relative to controls. The effect was independent of the sequence polymorphism in the region and persisted among individuals carrying the sequence-risk alleles. The odds of belonging to the type II diabetes group were increased by 6.1% for every 1% decrease in methylation.

A prospective study carried out in an independent population cohort revealed significant hypomethylation of young individuals that later progressed to type II diabetes, relative to the individuals who stayed healthy. Further genomic analysis revealed co-localization with gene enhancers and with binding sites for methylation-sensitive transcriptional regulators.

The data uncovered by this study showed that, “Low methylation levels at the analyzed sites were an early marker of type II diabetes and pointed to a novel mechanism by which early-onset, interindividual methylation variation at isolated nonpromoter genomic sites predisposes to type II diabetes.”

Related Links:

Hebrew University of Jerusalem




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.